Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

OnCore Login
Login to Oncore Network

Login to Oncore Network

Hoosier Cancer Research Network on Facebook

Hoosier Cancer Research Network on Facebook

GU00-9

A Multicenter Randomized Phase II Study of Docetaxel plus Vinorelbine and Doxetacel plus Estramustine in Combination for Hormone Refractory Prostate Cancer

Abstracts/Posters/Presentations:

  • N. M. Hahn, W. Fisher, R. Langdon, R. Zon, M. Browning, C. Calley, C. J. Sweeney. A Multicenter Randomized Phase II Study of Docetaxel (D) plus Vinorelbine (VRB) and Docetaxel plus Estramustine (EMP) in Combination for the Treatment of Hormone Refractory Prostate Cancer (HRPC): Hoosier Oncology Group GU00-9. Presented as part of the Scientific Program in the Genitourinary (Prostate) Cancer Poster Discussion, at the ASCO Annual Meeting, May 13 – 17, 2005, Orlando, FL. J Clin Oncology, Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005: 4568

Manuscripts/Articles:

  • Hahn NM, Marsh S, Fisher W, Langdon R, Zon R, Browning M, Johnson CS, Scott-Horton TJ, Li L, McLeod HL, Sweeney CJ. A Randomized Phase II Study of Docetaxel, Vinorelbine, and Estramustine in Combination in Hormone-Refractory Prostate Cancer with Pharmacogenetic Survival Analysis: A Hoosier Oncology Group Study GU00-9. Clin Cancer Res 2006;12(20) October 15, 2006.